Cerus (CERS) Asset Writedowns and Impairment (2022 - 2023)
Cerus' (CERS) quarterly Asset Writedowns and Impairment came in at $1.5 million in Q3 2023, up 375.46% quarter-over-quarter from -$542000.0 in Q4 2022.
Powered by 
Analysis
Cerus (CERS) Asset Writedowns and Impairment (2022 - 2023) Analysis & Trends
Cerus has disclosed Asset Writedowns and Impairment across 2 years of filings, most recently posting $1.5 million for Q3 2023.
- In Q3 2023, Asset Writedowns and Impairment changed N/A year-over-year to $1.5 million; the TTM figure through Dec 2023 stood at $951000.0 (changed N/A YoY), while the FY2023 annual figure was $1.7 million, changed N/A from the prior year.
- Asset Writedowns and Impairment came in at $1.5 million for Q3 2023 at Cerus, up from -$542000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $1.5 million in Q3 2023 to a low of -$542000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | Cerus | 504.42 Mn | 448.16 Mn | 29.53 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 1.49 Mn |
| Dec 31, 2022 | -542,000.00 |
| Mar 31, 2022 | 542,000.00 |